Karyopharm Therapeutics (KPTI) Share-based Compensation (2012 - 2025)

Karyopharm Therapeutics has reported Share-based Compensation for 14 years, with the latest figure at $3.9 million in Q4 2025.

• For the quarter ending Q4 2025, Share-based Compensation rose 1.01% year-over-year to $3.9 million; the trailing twelve-month figure through Dec 2025 stood at $14.0 million (down 25.53% YoY), and the FY2025 full-year result was $14.0 million, down 23.75% from the prior year.
• Share-based Compensation for Q4 2025 stood at $3.9 million, up from $2.8 million in the prior quarter.
• The five-year high for Share-based Compensation was $15.1 million in Q2 2022, with the low at $2.8 million in Q3 2025.
• Historically, Share-based Compensation has averaged $6.0 million across 5 years, with a median of $5.4 million in 2024.
• Annual changes were most pronounced in 2022 — Share-based Compensation surged 85.53% — and 2023, when it tumbled 59.85%.
• Karyopharm Therapeutics' Share-based Compensation stood at $6.9 million in 2021, then fell by 10.13% to $6.2 million in 2022, then fell by 16.05% to $5.2 million in 2023, then retreated by 25.43% to $3.9 million in 2024, then advanced by 1.01% to $3.9 million in 2025.
• The last three Share-based Compensation figures came in at $3.9 million (Q4 2025), $2.8 million (Q3 2025), and $3.6 million (Q2 2025), per Business Quant data.